Humanised anti-MAG antibody or functional fragment thereof

Details Humanised anti-MAG antibody or functional fragment thereof Humanised anti-MAG antibody or functional fragment thereof

2008-04-01

2011-12-06

Ewoldt, Gerald R (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S388100, C530S388150, C530S388220

Reexamination Certificate

active

08071731

ABSTRACT:
The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.

REFERENCES:
patent: 4873316 (1989-10-01), Meade et al.
patent: 5154924 (1992-10-01), Friden
patent: 5182107 (1993-01-01), Friden
patent: 5250414 (1993-10-01), Schwab et al.
patent: 5527527 (1996-06-01), Friden
patent: 5792743 (1998-08-01), Schachner
patent: 5833988 (1998-11-01), Friden
patent: 5932542 (1999-08-01), Filbin
patent: 6203792 (2001-03-01), Filbin
patent: 6399577 (2002-06-01), Filbin
patent: 6548061 (2003-04-01), Steeves et al.
patent: 6576607 (2003-06-01), Schachner
patent: 7612183 (2009-11-01), Ellis et al.
patent: 2004/0002790 (2004-01-01), Senn
patent: 2004/0170627 (2004-09-01), Irving et al.
patent: 2006/0165681 (2006-07-01), Ellis et al.
patent: 2007/0269427 (2007-11-01), Irving et al.
patent: 2008/0014195 (2008-01-01), Irving et al.
patent: 308434 (1993-09-01), None
patent: WO 00/63252 (2000-01-01), None
patent: WO 96/32959 (1996-01-01), None
patent: WO 95/22344 (1995-08-01), None
patent: WO 96/16990 (1996-06-01), None
patent: WO 97/01352 (1997-01-01), None
patent: WO 97/07810 (1997-03-01), None
patent: WO 95/12329 (1998-03-01), None
patent: WO 99/25378 (1999-05-01), None
patent: WO 99/53945 (1999-10-01), None
patent: WO 99/58679 (1999-11-01), None
patent: WO 00/31235 (2000-01-01), None
patent: WO 00/05364 (2000-02-01), None
patent: WO 00/43039 (2000-07-01), None
patent: WO 01/62907 (2001-08-01), None
patent: WO 02/062383 (2002-08-01), None
Lamminmaki, et al., J. Biol. Chem., vol. 276(39) pp. 36687-36694 (2001).
DePascalis, et al., 2002;169:3076-3084.
Riechman et al; Reshaping human antibodies for therapy, Nature, vol. 332, Mar. 1988, pp. 323-327.
Angal, et al., Mol. Immunol, 1993, vol. 30, pp. 105-108.
Bard, et al., Nature Medicine, vol. 8, No. 8, pp. 916-919, Aug. 2000.
Bartsch, et al., Neuron, vol. 15 pp. 1375-1381 (1995).
Beattie, et al. neuron, 2002, vol. 36, pp. 375-386.
Belayev, et al., Brain Research, vol. 739 pp. 88-96 (1996).
Benincosa, et al., Journal of Pharmacology & Experimental Therapuetics, vol. 292, No. 2, pp. 810-816. (2000).
Bickel, et al. Proc Natl. Acad. Sci. USA, 1993, vol. 90, pp. 2618-2622.
Bickel, et al., Advanced Drug Delivery Reviews, vol. 46 pp. 247-274 (1996).
Birch and Lenox, Monoclonal Antibodies: Principles and Applications, John Wilet and Sons Inc. pp. 299-335 (1995).
Broadwell, et al. Exp. Neurol., 1996, vol. 142, pp. 47-65.
Chen, et al., Nature vol. 403 (6768) pp. 434-439 (2000).
Coloma, et al., Pharma Research, vol. 17(3) pp. 266-276 (2000).
Crowe, et al., Nature Medicine, 1997, vol. 3, pp. 73-76.
Debellard, et al., Molecular and Cellular Neuroscience, vol. 7, No. 7, pp. 89-101 (1996).
Dehouck, et al., J. Cell Biol., 1997, pp. 877-889.
Descamps, et al., Am. J. Physiol., 1996, vol. 270, H1149-H1158.
DeSouza, et al., Novel Therpeutic Modalities to Address Nondrugable Protein Interaction Target., Neuropsychopharmacology, 2009, 34, 142-158.
Duffy, et al. Brain Res., 1987, vol. 420, pp. 32-38.
Friden, et al., J. Pharm. Exp. Ther., 1996, vol. 278, pp. 1491-1498.
Grandpre, et al., Nature, vol. 403(6768) pp. 439-444 (2000).
Green L.L. J Immunol Methods, Dec. 10, 1999, vol. 231, pp. 11-23.
Irving, et al., Acta Neuropathol (Berl), 2001, vol. 102, pp. 627-635.
Irving, et al., Journal of Cerebral Blood Flow and Metabolism, vol. 17, pp. 612-622 (1997).
Jakeman, et al., Exp. Neurol., vol. 154(1) pp. 170-184 (1998).
Kabat, et al., Sequences of Proteins of Immunological interest. U.S. Department of Health and Human Services, National Institutes of Health, 1987.
Kastrup, et al., Journal of the Neurological Sciences, vol. 166 pp. 91-99 (1999).
Kawamata, et al., Proc. Natl. Acad. Sci. USA, vol. 94(15) pp. 8179-8184.
Lassmann, et al., GLIA, vol. 19(2) pp. 104-110 (1997).
Li, et al., J. of Neurosci. Research, vol. 46(4) pp. 404-414 (1996).
Li, et al., J. of Neurosci. Research, vol. 51(2) pp. 210-217 (1998).
Li, et al., Nature, vol. 369(6483) pp. 747-750 (1994).
Lopate, et al., J. Neurol. Sci., vol. 188(1-2) pp. 67-72 (2001).
McKerracher, et al., Neuron, vol. 13 pp. 805-811 (1994).
Montag, et al, Neuron, vol. 13 pp. 229-246 (1994).
Moskowitz, et al., Brain Protection, Stroke, 2010; 41[suppl 1]:S85-S86.
Mukhopadhyay, et al., Neuron. vol. 13 pp. 757-767 (1994).
Niederost et al., J. of Neuroscience, vol. 22(23) pp. 10368-10376 (2002).
Pardridge, et al. Pharm. Res., 1995, vol. 12, pp. 807-816.
Poltorak, et al., J. of Cell Biology, vol. 105(4) pp. 1893-1899 (1987).
Prinjha, et al., Nature, vol. 403(6768) pp. 383-384 (2000).
Queen, et al., Proc. Natl. Acad. Sci. USA, 1989, vol. 86, pp. 10029-10032.
Ribotta, et al., J. Neurosci., vol. 20(13) pp. 5144-5152 (2000).
Roher, et al., Biochemistry, 2002, vol. 41, pp. 11080-11090.
Rouselle, et al., Journal of Pharmacology and Experimental Therapeutics, 2001, vol. 296, pp. 124-131.
Rouselle, et al., Mol. Pharm., 2000, vol. 57, pp. 679-686.
Saito, et al., Proc. Natl. Sci. USA, 1995, vol. 92, pp. 10227-10231.
Sambrook, et al., Molecular Cloning (A Laboratory Manual. Cold Spring Harbor Lab., 1989.
Sato, et al., Biochem. Biophys. Res. Comm., vol. 163(3) pp. 1473-1480 (1989).
Schafer, et al., Neuron, vol. 16(6) pp. 1107-1113 (1996).
Somogyvari-Vigh, et al., Regulatory Peptides, vol. 91 pp. 89-95 (2000).
Takle, et al., The identification of potent, selective and CNS penetraant furan-based inhibitors of—Raf kinase., 18 (2008) pp. 4373-4376.
Tang, et al., Mol. Cell. Neurosci., vol. 9(5-6) pp. 333-346 (1997).
Torigoe, et al., Exp. Neurology, vol. 150(2) pp. 254-262 (1997).
Umemori et al., Nature, vol. 367 pp. 572-576 (1994).
Valeriani et al., J. of Cerebral Blood Flow & Metabolism, vol. 20 pp. 765-771 (2000).
Vinson et al., Molecular and Cellular Neuroscience, vol. 22 pp. 344-352 (2003).
Wong et al., Nature Neuroscience, vol. 5(12) pp. 1302-1306 (2002).
Xu, et al., J. Biol. Chem.,1994, vol. 269, pp. 3469-3474.
Xu, et al., J. Neurosi., 2001, vol. 21, RC118.
Yin, et al., J. Neurosci., vol. 18(6) pp. 1953-1962 (1998).

Affiliated with

Also associated with

Rating

Humanised anti-MAG antibody or functional fragment thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Humanised anti-MAG antibody or functional fragment thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanised anti-MAG antibody or functional fragment thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4308472